Vietnam’s Ministry of Health (MOH) Grants Major Antiretroviral Therapy Transition

Friday, October 11, 2019

In July 2019, the World Health Organization (WHO) recommended a fixed dose combination of Tenofovir–Lamivudine–Dolutegravir (TLD) to treat HIV/AIDS as it is more effective and has fewer side effects, which results in fewer patients dropping out of treatment. By 2020, 41 PEPFAR countries and over 20 million PEPFAR patients will be on TLD. Vietnam has been resistant to importing and registering TLD because it has not had a clinical trial. After almost two years of advocacy by USAID (including garnering high-level letters of support from PEPFAR, Global Fund, WHO, and the U.S. Ambassador to Vietnam) and providing MOH with evidence/data collected on TLD, MOH has finally granted a Marketing Authorization for TLD.

So What? The Marketing Authorization will allow PEPFAR and the Global Fund to immediately start a small number of patients on TLD and most importantly, it will allow Vietnam’s Social Health Insurance to procure TLD for distribution in 2021 to a majority of the country’s HIV patients on treatment.

Last updated: November 18, 2019

Share This Page